KLRK1 and neoplasm: In vivo, BsAbs combined with NKG2D-CAR NK cells significantly enhanced tumor clearance and prolonged survival, demonstrating durable efficacy and the feasibility of an "off-the-shelf" cellular-immunotherapy approach 81, 84.